Oral Proteins And Peptides Market Report 2026

Oral Proteins And Peptides Market Overview

• Oral Proteins And Peptides market size has reached to $1.56 billion in 2025 • Expected to grow to $4.26 billion in 2030 at a compound annual growth rate (CAGR) of 22.2% • Growth Driver: Growing Biopharmaceutical Industry • Market Trend: Technological Advancements in the Oral Proteins and Peptides Market to Enhance Bioavailability and Patient Compliance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Proteins And Peptides Market?

Oral Proteins and Peptides refer to therapeutic proteins and peptides administered orally, typically in pills, capsules, or other ingestible formats. These biologically active molecules are designed to treat various medical conditions by leveraging their specific actions within the body. The main drug types of oral proteins and peptides are linaclotide, calcitonin, insulin, plecanatide, and octreotide. The biological targets are guanylate cyclase-c (gc-c), insulin receptor, oxalate, and others, and the different mechanisms of action are receptor stimulation, substrate degradation, and others. It is used for various applications such as gastrointestinal disorders, bone disease, neurological disorders, diabetes, metabolic disorders, hormonal disorders, and cancer.

What Is The Oral Proteins And Peptides Market Growth Forecast?

The oral proteins and peptides market size is expected to see exponential growth in the next few years. It will grow to $4.26 billion in 2030 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to development of novel delivery technologies for oral proteins, expansion of chronic disease management programs, rising adoption of personalized and combination therapies, increasing healthcare expenditure on metabolic and hormonal disorders, integration of digital adherence and monitoring tools. Major trends in the forecast period include rising adoption of oral insulin and other therapeutic peptides, growth in personalized medicine and targeted oral protein therapies, increasing focus on gastrointestinal disorder treatments, expansion of oral protein formulations for diabetes and metabolic disorders, advancement in long-acting and combination oral protein products.

What Is The Driver Of The Oral Proteins And Peptides Market?

The growing biopharmaceutical industry is expected to propel the growth of the oral proteins and peptides market going forward. The biopharmaceutical industry is a sector within the broader pharmaceutical industry that focuses on developing, producing, and commercializing drugs derived from biological sources. The growth of the biopharmaceutical industry is due to advancements in biotechnology, growing demand for personalized medicine, increasing prevalence of chronic diseases, and rising investment in research and development. Oral proteins and peptides in biopharmaceuticals offer potential for non-invasive delivery of therapeutics, enhancing patient compliance and reducing the need for injections. They can target specific diseases with improved stability and absorption in the digestive system. For instance, in October 2025, according to the Bioscience and Health Technology Sector, a UK-based government statistics, in 2023/2024, there were 6,170 businesses operating in the UK life sciences industry across 7,320 companies. These businesses employed 359,600 people and generated £146.9 ($169.69) billion in turnover. Therefore, the growing biopharmaceutical industry is driving the growth of the oral proteins and peptides industry.

Key Players In The Global Oral Proteins And Peptides Market

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Global Oral Proteins And Peptides Market Trends and Insights

Major companies operating in the oral proteins and peptides market are focusing on developing innovative formulation technologies to enhance peptide stability, permeability, and bioavailability in oral dosage forms. These advancements aim to overcome traditional challenges such as enzymatic degradation and poor absorption in the gastrointestinal tract. For instance, in August 2025, BioMed X, a Germany-based biomedical research institute, launched a new collaboration with Novo Nordisk, a Denmark-based pharmaceutical company, to accelerate the development of next-generation oral peptide delivery technologies. The partnership will explore novel molecular strategies and delivery mechanisms to enable safe, effective, and patient-friendly oral peptide therapeutics. By integrating BioMed X’s early-stage research capabilities with Novo Nordisk’s expertise in peptide-based medicines, the collaboration aims to advance breakthrough oral drug delivery solutions and expand the therapeutic potential of peptide medicines across metabolic and chronic diseases.

What Are Latest Mergers And Acquisitions In The Oral Proteins And Peptides Market?

In April 2023, Chiesi Farmaceutici S.p.a., an Italy-based pharmaceutical company, acquired Amryt Pharma Plc for an undisclosed amount. This acquisition enables Chiesi to harness Amryt's distinctive products and promising pipeline, reinforcing its dedication to rare diseases and enhancing its biopharmaceutical capabilities. Amryt Pharma Plc is a UK-based provider of oral proteins and peptides.

What Defines the Oral Proteins And Peptides Market?

The oral proteins and peptides market consists of sales of protein supplements, peptide-based drugs, and therapeutic formulations designed for oral administration. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Proteins And Peptides Market Report 2026?

The oral proteins and peptides market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral proteins and peptides industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.